All In Biotech

Drug Trial Radar · NCT00000136

Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)

Foscarnet-Ganciclovir CMV Retinitis Trial

Last checked: Nov 19, 2026Latest source record: Oct 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

234

Actual

Start

Mar 1990

Primary completion

Oct 1991

Study completion Oct 1991

Sponsor

Lead sponsor
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Eye Institute (NEI); Johns Hopkins University; University of Wisconsin, Madison; Baylor College of Medicine; Louisiana State University Health Sciences Center in New Orleans; New York Presbyterian Hospital; Icahn School of Medicine at Mount Sinai; NYU Langone Health; Northwestern University; University of California, Los Angeles; University of California, San Diego; University of California, San Francisco; University of Miami; University of Massachusetts, Worcester; Memorial Sloan Kettering Cancer Center
First posted
Sep 24, 1999

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the relative safety and efficacy of ganciclovir and foscarnet as initial treatment of patients with cytomegalovirus (CMV) retinitis.

Conditions

  • HIV Infections
  • Cytomegalovirus Retinitis

Interventions

  • FoscarnetDrug

    60 mg/kg every 8 hours, 90 mg/kg/day

  • GanciclovirDrug

    5 mg/kg every 12 hours, 5 mg/kg every 24 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MortalityTime frame: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.